Cited 6 time in
Cited 6 time in
PiB-PET Imaging-Based Serum Proteome Profiles Predict Mild Cognitive Impairment and Alzheimer's Disease
- PiB-PET Imaging-Based Serum Proteome Profiles Predict Mild Cognitive Impairment and Alzheimer's Disease
- Kang, S[Kang, Seokjo]; Jeong, H[Jeong, Hyobin]; Baek, JH[Baek, Je-Hyun]; Lee, SJ[Lee, Seung-Jin]; Han, SH[Han, Sun-Ho]; Cho, HJ[Cho, Hyun Jin]; Kim, H[Kim, Hee]; Hong, HS[Hong, Hyun Seok]; Kim, YH[Kim, Young Ho]; Yi, EC[Yi, Eugene C.]; Seo, SW[Seo, Sang Won]; Na, DL[Na, Duk L.]; Hwang, D[Hwang, Daehee]; Mook-Jung, I[Mook-Jung, Inhee]
- DGIST Authors
- Hwang, D[Hwang, Daehee]
- Issue Date
- Journal of Alzheimers Disease, 53(4), 1563-1576
- Article Type
- Alzheimer' s Disease (AD); Biological Marker; Biomarker; Blood Clotting Factor Xiii A1 Polypeptide; Blood Sampling; Brain Scintiscanning; Brain Tissue; Controlled Study; Dermcidin; Early Diagnosis; Enzyme Linked Immunosorbent Assay; Gene Expression; Gene Identification; Gene Ontology; Genomics; Human; LC-MS/MS; Liquid Chromatography; Mild Cognitive Impairment; Molecular Pathology; Neuropathology; Pittsburgh Compound B; Positron-Emission Tomography (PET); Priority Journal; Proprotein Convertase Subtilisin Kexin Type 9; Protein Blood Level; Protein Degradation; Protein Protein Interaction; Proteome; Proteomics; Serum; Tandem Mass Spectrometry; Unclassified Drug; Upregulation; Western Blotting
- Development of a simple, non-invasive early diagnosis platform of Alzheimer's disease (AD) using blood is urgently required. Recently, PiB-PET imaging has been shown to be powerful to quantify amyloid-β plaque loads leading to pathophysiological alterations in AD brains. Thus, there has been a need for serum biomarkers reflecting PiB-PET imaging data as an early diagnosis platform of AD. Here, using LC-MS/MS analysis coupled with isobaric tagging, we performed comprehensive proteome profiling of serum samples from cognitively normal controls, mild cognitive impairment (MCI), and AD patients, who were selected using PiB-PET imaging. Comparative analysis of the proteomes revealed 79 and 72 differentially expressed proteins in MCI and AD, respectively, compared to controls. Integrated analysis of these proteins with genomic and proteomic data of AD brain tissues, together with network analysis, identified three biomarker candidates representing the altered proteolysis-related process in MCI or AD: proprotein convertase subtilisin/kexin type 9 (PCSK9), coagulation factor XIII, A1 polypeptide (F13A1), and dermcidin (DCD). In independent serum samples of MCI and AD, we confirmed the elevation of the candidates using western blotting and ELISA. Our results suggest that these biomarker candidates can serve as a potential non-invasive early diagnosis platform reflecting PiB-PET imaging for MCI and AD.
- Institute of Physics Publishing
- Related Researcher
Systems Biology and Medicine Lab
Multilayered spatiotemporal networks; Regulatory motifs or pathways; Metabolite-protein networks; Network stochasticity; Proteomics and informatics
There are no files associated with this item.
- Department of New BiologySystems Biology and Medicine Lab1. Journal Articles
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.